Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis
Valent, Peter , Escribano, Luís, Broesby‐Olsen, Sigurd , Hartmann, Karin , Grattan, Clive , Niedoszytko, Marek , Nedoszytko, Bogusław , Elberink, J. N. G. Oude, Kristensen, Thomas Kielsgaard , Butterfield, Joseph H. , Triggiani, Massimo , Álvarez‐Twöse, Iván , Reiter, Andreas , Sperr, Wolfgang R. , Sotlar, Karl , Yavuz, Selim , Kluin‐Nelemans, Hanneke C. , Hermine, Olivier , Radia, Deepti , Doormaal, J. J. van, Orfao, A., Siebenhaar, Frank , Schwartz, Lawrence B. , Maurer, Marcus , Horny, H.‐P., Akin, Cem , Metcalfe, Dean D. , Arock, Michel , Brockow, Knut , Gotlib, Jason , Orfao, A., Castells, Mariana , Sperr, Wolfgang , Valent, Peter , Hermine, Olivier , Akin, Cem , Arock, Michel , Kluin-Nelemans, Hanneke C

Allergy | May 19, 2014 | Volume: 69 | Issue: 10 | Pages: 1267-1274

10.1111/all.12436 | PMID 24836395 Get It

AbstractMastocytosis is an emerging differential diagnosis in patients with more or less specific mediator‐related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, however, skin lesions are absent, which represents a diagnostic challenge. In the light of this unmet need, we developed a diagnostic algorithm for patients with suspected mastocytosis. In adult patients with typical lesions of mastocytosis in the skin, a bone marrow (BM) biopsy should be considered, regardless of the basal serum tryptase concentration. In adults without skin lesions who suffer from mediator‐related or other typical symptoms, the basal tryptase level is an important parameter. In those with a slightly increased tryptase level, additional investigations, including a sensitive KIT mutation analysis of blood leucocytes or measurement of urinary histamine metabolites, may be helpful. In adult patients in whom (i) KIT D816V is detected and/or (ii) the basal serum tryptase level is clearly increased (>25–30 ng/ml) and/or (iii) other clinical or laboratory features suggest the presence of ‘occult’ mastocytosis or another haematologic neoplasm, a BM investigation is recommended. In the absence of KIT D816V and other signs or symptoms of mastocytosis or another haematopoietic disease, no BM investigation is required, but the clinical course and tryptase levels are monitored in the follow‐up. In paediatric patients, a BM investigation is usually not required, even if the tryptase level is increased. Although validation is required, it can be expected that the algorithm proposed herein will facilitate the management of patients with suspected mastocytosis and help avoid unnecessary referrals and investigations.
The past, present, and future of telemedicine for Parkinson's disease
Achey, Meredith A. , Aldred, Jason , Aljehani, Noha, Bloem, Bastiaan R. , Biglan, Kevin , Chan, Piu, Cubo, Esther , Dorsey, E. Ray , Guttman, Mark, Hassan, Anhar , Khandhar, Suketu M., Spindler, Meredith , Haak, Pieter van den , Walker, Richard , Wilkinson, Jayne , Force, on behalf of the International Parkinson and Movement Disorder Society Telemedicine Task, Goetz, Christopher G. , Mari, Zoltan K. , Tanner, Caroline M. , Force, on behalf of the International Parkinson and Movement Disorder Society Telemedicine Task

Movement Disorders | May 17, 2014 | Volume: 29 | Issue: 7 | Pages: 871-883

10.1002/mds.25903 | PMID 24838316 Get It

ABSTRACT Travel distance, growing disability, and uneven distribution of doctors limit access to care for most Parkinson's disease (PD) patients worldwide. Telemedicine, the use of telecommunications technology to deliver care at a distance, can help overcome these barriers. In this report, we describe the past, present, and likely future applications of telemedicine to PD. Historically, telemedicine has relied on expensive equipment to connect single patients to a specialist in pilot programs in wealthy nations. As the cost of video conferencing has plummeted, these efforts have expanded in scale and scope, now reaching larger parts of the world and extending the focus from care to training of remote providers. Policy, especially limited reimbursement, currently hinders the growth and adoption of these new care models. As these policies change and technology advances and spreads, the following will likely develop: integrated care networks that connect patients to a wide range of providers; education programs that support patients and health care providers; and new research applications that include remote monitoring and remote visits. Together, these developments will enable more individuals with PD to connect to care, increase access to expertise for patients and providers, and allow more‐extensive, less‐expensive participation in research. © 2014 International Parkinson and Movement Disorder Society
Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xeno
Mladek, Ann C. , Carlson, Brett L. , Boakye‐Agyeman, Felix , Kizilbash, Sani H. , Boakye-Agyeman, Felix, Reid, Joel, Gupta, Shiv K. , Bakken, Katrina K. , Schroeder, Mark A. , Reid, Joel M. , Sarkaria, Jann N. , Kizilbash, Sani H , Mladek, Ann C

Clinical Cancer Research | May 17, 2014 | Volume: 20 | Issue: 14 | Pages: 3730-3741

10.1158/1078-0432.ccr-13-3446 | PMID 24838527 Get It

Abstract Purpose: Effective sensitizing strategies potentially can extend the benefit of temozolomide (TMZ) therapy in patients with glioblastoma (GBM). We previously demonstrated that robust TMZ-sensitizing effects of the [poly (ADP-ribose) polymerase] (PARP) inhibitor veliparib (ABT-888) are restricted to TMZ-sensitive GBM xenografts. The focus of this study is to provide an understanding for the differential sensitization in paired TMZ-sensitive and -resistant GBM models. Experimental Design: The impact of veliparib on TMZ-induced cytotoxicity and DNA damage was evaluated in vitro and in vivo in models of acquired TMZ resistance (GBM12TMZ-mgmtHigh, GBM12TMZ-mgmtLow, and U251TMZ), inherent TMZ resistance (T98G), and TMZ-sensitive (U251 and GBM12). In vivo drug efficacy, pharmacokinetics, and pharmacodynamics were analyzed using clinically relevant dosing regimens. Results: Veliparib enhanced TMZ cytotoxicity and DNA-damage signaling in all GBM models in vitro with more pronounced effects in TMZ-resistant lines at 3 to 10 μmol/L veliparib. In vivo, combined TMZ/veliparib, compared with TMZ alone, significantly delayed tumor growth and enhanced DNA-damage signaling and γH2AX levels in the sensitive GBM12 xenograft line but not in the resistant GBM12TMZ lines. The pharmacokinetic profile of veliparib was similar for GBM12 and GBM12TMZ tumors with Cmax (∼1.5 μmol/L) in tissue significantly lower than concentrations associated with optimal in vitro sensitizing effects for resistant tumors. In contrast, robust suppression of PARP-1 expression by shRNA significantly increased TMZ sensitivity of U251TMZ in vitro and in vivo. Conclusions: In vitro cytotoxicity assays do not adequately model the therapeutic index of PARP inhibitors, as concentrations of veliparib and TMZ required to sensitize TMZ-resistant cancer cells in vivo cannot be achieved using a tolerable dosing regimen. Clin Cancer Res; 20(14); 3730–41. ©2014 AACR.
Assessment of Nuclear Nanomorphology Marker to Improve the Detection of Malignancy From Bile Duct Biopsy Specimens
Uttam, Shikhar , Staton, Kevin D., Bista, Rajan K., IIyas, Sumera I, Slivka, Adam, Liu, Yang , I Ilyas, Sumera, Hartman, Douglas J. , Krasinskas, Alyssa M. , Brand, Randall E.

American Journal of Clinical Pathology | May 16, 2014 | Volume: 141 | Issue: 6 | Pages: 884-891

10.1309/ajcpxqd0nsjnk0cx | PMID 24838334 Get It

Abstract Objectives: The accurate diagnosis of malignancy from small bile duct biopsy specimens is often challenging. This proof-of-concept study assessed the feasibility of a novel optical technology, spatial-domain low-coherence quantitative phase microscopy (SL-QPM), that assesses nanoscale structural alterations in epithelial nuclei for improving the diagnosis of malignancy in bile duct biopsy specimens. Methods: The SL-QPM analysis was performed on standard histology specimens of bile duct biopsy specimens from 45 patients. We analyzed normal cells with benign follow-up, histologically normal cells with pancreaticobiliary malignancy, and malignant epithelial cells. Results: The SL-QPM–derived nuclear nanomorphology marker can not only distinguish benign and malignant epithelial cells but can also detect features of malignancy in those cells normal by light microscopy with a discriminatory accuracy of 0.90. When combining pathology with SL-QPM, the sensitivity is improved to 88.5% from 65.4% of conventional pathology, while maintaining 100% specificity. Conclusions: SL-QPM–derived nuclear nanomorphology markers represent a novel approach for detecting malignancy from histologically normal-appearing epithelial cells, with potential as an adjunctive test in patients with negative or inconclusive pathologic diagnosis on bile duct biopsy specimens.
The Feasibility and Impact of Midnight Routine Blood Draws on Laboratory Orders and Processing Time
Sorita, Atsushi , Patterson, Aaron, Landazuri, Patrick , De-Lin, Stacy, Fischer, Colleen, Husk, Gregg , Sivaprasad, Latha, Landazuri, Patrick

American Journal of Clinical Pathology | May 16, 2014 | Volume: 141 | Issue: 6 | Pages: 805-810

10.1309/ajcppl8kfh3kfhnv | PMID 24838324 Get It

Optimization of Vancomycin Dosing in Very Low-Birth-Weight Preterm Neonates
Teng, Christine B. , Koshaish, Jena, Johnson, Kent , Graner, Kevin, Banerjee, Ritu , Madigan, Theresa , Johnson, Kent R, Graner, Kevin K

American Journal of Perinatology | May 16, 2014 | Volume: 32 | Issue: 01 | Pages: 083-086

10.1055/s-0034-1376183 | PMID 24839147 Get It

Specific pattern of gadolinium enhancement in spondylotic myelopathy
Flanagan, Eoin P. , Krecke, Karl N. , Marsh, Richard W., Weinshenker, Brian G. , Giannini, Caterina , Keegan, B. Mark , Flanagan, E P , Weinshenker, Brian G

Annals of Neurology | May 16, 2014 | Volume: 76 | Issue: 1 | Pages: 54-65

10.1002/ana.24184 | PMID 24838831 Get It

Objective To highlight a specific under‐recognized radiological feature of spondylotic myelopathy often resulting in misdiagnosis. Methods Patients evaluated between January 1, 1996 and December 31, 2012 who met the following criteria were included: (1) spondylotic myelopathy was suspected, (2) gadolinium enhancement was detected, and (3) spinal surgery was performed. Results Fifty‐six patients (70% men) whose median age was 53.5 years (range = 24–80) were included. Spinal cord magnetic resonance imaging (cervical in 52; thoracic in 4) revealed longitudinal spindle‐shaped T2‐signal hyperintensity (100%) and cord enlargement (79%) accompanied by a characteristic pancakelike transverse band of gadolinium enhancement in 41 (73%), typically immediately caudal to the site of maximal spinal stenosis. Forty (71%) patients were initially diagnosed with neoplastic or inflammatory myelopathies, and decompressive surgery was delayed by a median of 11 months (range = 1–64). Spinal cord biopsy in 6 did not reveal any alternative diagnosis. Ninety‐five percent were stable or improved. Gadolinium enhancement persisted in 75% at 12 months, raising concern about the accuracy of the initial diagnosis. Twenty patients required a gait aid (36%) at last follow‐up (median = 60 months, range = 10–172). The need for a gait aid preoperatively ( p = 0.005), but not delay of surgery, predicted the need for gait aid at final follow‐up. Interpretation Transverse pancakelike gadolinium enhancement associated with and just caudal to the site of maximal stenosis and at the rostrocaudal midpoint of a spindle‐shaped T2 hyperintensity suggests that spondylosis is the cause of the myelopathy. Persistent enhancement for months to years following decompressive surgery is common. Recognition is important to prevent inappropriate interventions or delay in consideration of a potentially beneficial decompressive surgery. Ann Neurol 2014;76:54–65
A novel VCP mutation underlies scapuloperoneal muscular dystrophy and dropped head syndrome featuring lobulated fibers
Liewluck, Teerin , Milone, Margherita , Mauermann, Michelle L. , Castro‐Couch, Melissa, Cerhan, Jane H. , Murthy, Naveen S. , Liewluck, T , Mauermann, Michelle L

Muscle & Nerve | May 16, 2014 | Volume: 50 | Issue: 2 | Pages: 295-299

10.1002/mus.24290 | PMID 24838343 Get It

ABSTRACTIntroduction: Valosin‐containing protein (VCP) is a ubiquitously expressed, multifunctional AAA‐ATPase protein. Its dominant mutations cause hereditary inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD) or amyotrophic lateral sclerosis. The pattern of muscle weakness in IBMPFD patients is variable and includes limb‐girdle, scapuloperoneal, distal, or axial distributions. Case Report: We report a 63‐year‐old man with progressive scapuloperoneal weakness, head drop, and hyperCKemia since age 40 years. Electromyography showed myopathic changes and rare myotonic discharges. Muscle biopsy revealed numerous lobulated fibers, few fibers with glycogen accumulation, and rare fibers with polyglucosan bodies. Rimmed vacuoles and congophilic inclusions, often seen in IBMPFD, were absent. VCP sequencing identified a novel heterozygous c. 1160G>A mutation resulting in p.Asn387Ser substitution. Conclusions: Our patient broadens the pathological spectrum of VCP‐myopathy and emphasizes the importance of VCP analysis in patients with scapuloperoneal muscular dystrophy despite the absence of Paget disease, dementia, rimmed vacuoles, or intracellular amyloid deposition. Muscle Nerve 50:295–299, 2014
Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation
Guérin, A., Mody, Reema , Fok, Beverly, Lasch, Karen, Zhou, Zheng‐Yi , Wu, E.Q. , Zhou, Weiling , Talley, Nicholas J.

Alimentary Pharmacology & Therapeutics | May 16, 2014 | Volume: 40 | Issue: 1 | Pages: 83-92

10.1111/apt.12789 | PMID 24832002 Get It

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study
Grothey, Axel, Flick, E. Dawn, Cohn, Allen Lee, Bekaii‐Saab, Tanios , Bendell, Johanna C. , Kozloff, Mark, Roach, Nancy, Mun, Yong, Fish, Susan, Hurwitz, Herbert I. , Bekaii-Saab, Tanios S

Pharmacoepidemiology and Drug Safety | May 16, 2014 | Volume: 23 | Issue: 7 | Pages: 726-734

10.1002/pds.3633 | PMID 24830357 Get It

ABSTRACTPurposeThis analysis from Avastin® Registries: Investigation of Effectiveness and Safety (ARIES) examined the association between exposure to bevacizumab after disease progression (PD) and postprogression survival (PPS) in bevacizumab‐exposed metastatic colorectal cancer (mCRC) through the application of time‐dependent and time‐fixed analytical methods.MethodsPatients with mCRC who were treated with first‐line bevacizumab and who survived first PD (PD1) were included. A time‐dependent Cox regression model was fitted to assess the effect of cumulative bevacizumab exposure on PPS, while controlling for potential confounders. In addition to support findings from previous studies, a modified intent‐to‐treat (mITT) analysis compared PPS in patients who received bevacizumab beyond disease progression (BBP) with those who did not (No‐BBP).ResultsOf 1550 patients, 1199 survived PD1 and had a median PPS of 13.4 months. Cumulative bevacizumab exposure was associated with improved PPS (p = 0.0040). After adjusting for confounders, the hazard ratios (HRs) for PPS decreased, on average, by 1.2% (range, 1.1–1.3%) with each additional dose of bevacizumab. In the mITT analysis, the median PPS for BBP (n = 438) was 14.4 months vs 10.6 months with for No‐BBP (n = 667). BBP was found to be independently associated with longer PPS in a multivariable Cox regression analysis (HR, 0.84; 95% confidence interval, 0.73–0.97). Protocol‐specified adverse events suspected to be associated with bevacizumab occurred in 13.0% of patients with BBP.ConclusionThis analysis supports the observation that bevacizumab exposure after PD1 is associated with longer PPS in mCRC. Copyright © 2014 John Wiley & Sons, Ltd.